-5%
Tildex, when used together with acetylsalicylic acid (ASA), is prescribed to help prevent atherothrombotic complications in adults with acute coronary syndrome (ACS) or in patients who have previously experienced myocardial infarction (MI) and remain at high risk for future thrombotic cardiovascular events.
Ticagrelor is an antiplatelet medication that works by selectively blocking the P2Y12 receptor on platelets. This receptor normally contributes to platelet activation and aggregation through signaling pathways involving Gi proteins and related mediators. By inhibiting this receptor, ticagrelor reduces platelet clumping and lowers the formation of blood clots, thereby decreasing the risk of heart attack and ischemic stroke.
Ticagrelor has been tolerated in single doses up to 900 mg. Overdose may lead to gastrointestinal disturbances, shortness of breath, or ventricular pauses. Symptomatic and supportive treatment should be provided.